Sign in

4519 on Tokyo Stock Exchange

Chugai Pharmaceutical Co.

Logo: Chugai Pharmaceutical Vectorization: Kopiersperre, Public domain, via Wikimedia Commons4

Japanese pharmaceutical company

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo.2 It employed 6,872 people.1 Its shares trade on Tokyo Stock Exchange under the symbol 4519.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1925Founded1

Compare with another stock.

  • Ticker4519 on Tokyo Stock Exchange1
  • HeadquartersTokyo1
  • Websitewww.chugai-pharm.co.jp/english
  • Legal formForeign company not registered with the RCS, kabushiki gaisha1
  • LEI529900T9LAII161DCN953
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered address北区浮間５丁目５番１号, 115-0051 東京都, Japan3
  • Registered withNational Tax Agency, 50115010029003

See how the biggest companies compare on our leaderboards

Nihonbashi mitsui tower01s3872
Photo: 663highland, CC BY 2.5, via Wikimedia Commons6

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.2

The story

Timeline

This is a timeline of important events of Chugai Pharmaceutical.

1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines

1927: Start of the first own production

1930: Salobrocanon, an analgesic (pain reliever ) and antipyretic, is launched

1937: Calcium bromide production begins

1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo

1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga

1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt

Read the full text

1946: Construction of the plant in Kamagiishi

1951: Guronsan, a drug to detoxify and restore liver function, is launched

1952: Varsan, a perspiration insecticide, is launched

1955: Chugai became a public company.

1956: The stock is listed on the Tokyo Stock Exchange

1957: Construction of the Ukima plant

1960: Establishment of a research center (Takada Research Laboratory, Tokyo)

1967: Foundation of Fukushima Kasai Co Ltd.

1961 – Developed patents for synthesis of vitamin A

1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.

1971: Construction of the factory in Fujieda

1975: Picibanil, a cancer drug, is launched

1982: Opening of a branch in New York

1986: Opening of a branch in London

1989: Acquisition of Gen-Probe Incorporated (USA)

1990: Epogin launched

1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid

1996 – Released anti-viral chemotherapeutic agent Hivid (HIV reverse transcriptase inhibitor)

1997 – Released HIV protease inhibitor Invirase

1999 – Released immunosuppressive agent Cellcept

2000 – Released antiemetic drug Kytril, developed to combat the side effects of chemotherapy

2001 – Produced anti-influenza virus Tamiflu (Roche)

2002: Start of the alliance with Roche

2003: Xeloda, a cancer drug, is launched

2005: Actemra launched

2007: Copegus, an antiviral, Avastin, a cancer drug, and Tarceva, a cancer drug launched

2011 – Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis

2014: Launch of Kadcyla, a cancer drug, Chugai Pharma China Co Ltd. founded

2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.

2016: Cooperation between Osaka University and Chugai

2018: Tecentriq, a cancer drug, is launched

2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica

From Wikipedia’s article on Chugai, shared under CC BY-SA 4.0.5

Timeline

  1. 1925Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Dec 16, 2026Phase 3 trial readout expected Phase 3 trial of Satralizumab in NMDAR Autoimmune Encephalitis, run by Hoffmann-La Roche: primary completion expected Dec 16, 2026 (ClinicalTrials.gov NCT05503264).7
  2. Jan 30, 2027Phase 3 trial readout expected Phase 3 trial of Afimkibart in Moderately to Severely Active Ulcerative Colitis, run by Hoffmann-La Roche: primary completion expected Jan 30, 2027 (ClinicalTrials.gov NCT06589986).8
  3. Apr 18, 2027Phase 3 trial readout expected Phase 3 trial of Crovalimab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, run by Hoffmann-La Roche: primary completion expected Apr 18, 2027 (ClinicalTrials.gov NCT04432584).9
  4. Jun 15, 2027Phase 2 trial readout expected Phase 2 trial of DONQ52 in Celiac Disease: primary completion expected Jun 15, 2027 (ClinicalTrials.gov NCT07239336).10
  5. Sep 23, 2027Phase 3 trial readout expected Phase 3 trial of NXT007 and Human Coagulation Factor VIII in Hemophilia A, run by Hoffmann-La Roche: primary completion expected Sep 23, 2027 (ClinicalTrials.gov NCT07416526).11

Drug trials and FDA: recently

  1. May 19, 2026Phase 3 trial completed Phase 3 trial of Divarasib, Sotorasib and others in Non-Small Cell Lung Cancer, run by Hoffmann-La Roche: primary completion May 19, 2026, no results posted yet (ClinicalTrials.gov NCT06497556).12
  2. Nov 20, 2025Phase 3 trial completed Phase 3 trial of Satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), run by Hoffmann-La Roche: primary completion Nov 20, 2025, no results posted yet (ClinicalTrials.gov NCT05271409).13
  3. Jul 4, 2025Phase 3 trial completed Phase 3 trial of Crovalimab in Atypical Hemolytic Uremic Syndrome, run by Hoffmann-La Roche: primary completion Jul 4, 2025, results posted Sep 9, 2026 (ClinicalTrials.gov NCT04958265).14

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14